JP2022502448A5 - - Google Patents
Info
- Publication number
- JP2022502448A5 JP2022502448A5 JP2021517766A JP2021517766A JP2022502448A5 JP 2022502448 A5 JP2022502448 A5 JP 2022502448A5 JP 2021517766 A JP2021517766 A JP 2021517766A JP 2021517766 A JP2021517766 A JP 2021517766A JP 2022502448 A5 JP2022502448 A5 JP 2022502448A5
- Authority
- JP
- Japan
- Prior art keywords
- present
- pharmaceutically acceptable
- compound
- pharmaceutical composition
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811160163.0A CN110963958B (zh) | 2018-09-30 | 2018-09-30 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
| CN201811160163.0 | 2018-09-30 | ||
| PCT/CN2019/109428 WO2020064004A1 (zh) | 2018-09-30 | 2019-09-30 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502448A JP2022502448A (ja) | 2022-01-11 |
| JP2022502448A5 true JP2022502448A5 (https=) | 2022-12-06 |
| JP7338896B2 JP7338896B2 (ja) | 2023-09-05 |
Family
ID=69949744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517766A Active JP7338896B2 (ja) | 2018-09-30 | 2019-09-30 | Ｍｄｍ２阻害剤、その調製方法、医薬組成物および応用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11299460B2 (https=) |
| EP (1) | EP3858812B1 (https=) |
| JP (1) | JP7338896B2 (https=) |
| KR (1) | KR102610545B1 (https=) |
| CN (2) | CN110963958B (https=) |
| AU (1) | AU2019351530B2 (https=) |
| ES (1) | ES3013859T3 (https=) |
| WO (1) | WO2020064004A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114853731B (zh) * | 2021-02-04 | 2026-02-06 | 上海长森药业有限公司 | 一种双功能mdm2蛋白降解剂，及其制备方法、药物组合物和应用 |
| WO2023089375A1 (en) * | 2021-11-22 | 2023-05-25 | Ligature Therapeutics Pte, Ltd. | Therapeutic compounds and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US9376425B2 (en) * | 2011-09-27 | 2016-06-28 | Amgen, Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014134201A1 (en) * | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| CN105358530A (zh) * | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| BR112016010564A2 (pt) * | 2013-11-11 | 2017-10-10 | Amgen Inc | terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres |
| US10759808B2 (en) * | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| SG11201808728QA (en) * | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| WO2018092020A1 (en) * | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
-
2018
- 2018-09-30 CN CN201811160163.0A patent/CN110963958B/zh active Active
-
2019
- 2019-09-30 KR KR1020217013158A patent/KR102610545B1/ko active Active
- 2019-09-30 EP EP19864128.4A patent/EP3858812B1/en active Active
- 2019-09-30 JP JP2021517766A patent/JP7338896B2/ja active Active
- 2019-09-30 ES ES19864128T patent/ES3013859T3/es active Active
- 2019-09-30 CN CN201980064565.7A patent/CN112867708B/zh active Active
- 2019-09-30 WO PCT/CN2019/109428 patent/WO2020064004A1/zh not_active Ceased
- 2019-09-30 AU AU2019351530A patent/AU2019351530B2/en active Active
- 2019-09-30 US US17/281,368 patent/US11299460B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6462045B2 (ja) | スルフォラファンの単離及び精製 | |
| JP2013522229A5 (https=) | ||
| AU2018260616B2 (en) | Treating and preventing kidney damage | |
| EP0689836A1 (en) | Spirooxathiolane-quinuclidine derivative for the treatment of xerostomia | |
| EP2124930B1 (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
| JP2022502448A5 (https=) | ||
| EP2575807B1 (en) | Formulation based on sulpiride and a synergistic homeopathic composition for treatment of depressive syndrome | |
| KR20200065012A (ko) | 글리신 뇌병증 치료를 위한 벤조에이트 함유 조성물의 사용 | |
| JP5961034B2 (ja) | 安定化方法 | |
| EP2985037B1 (en) | A pharmaceutical composition comprising palmitoylethanolamid and cytidine-diphosphocholine | |
| KR101082802B1 (ko) | 8-하이드록시클로미프라민 또는 그의 염을 포함하는 조루의 예방 또는 치료용 약학 조성물 | |
| JP2023501967A (ja) | ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
| CN104645334B (zh) | N‑乙酰半胱氨酸活性炭组合物及其制备方法和应用 | |
| ES2309513T3 (es) | Uso de derivados de acido fenoxiacetico para tratar vejiga hiperactiva. | |
| KR930011994B1 (ko) | 파라세타몰의 생체이용율을 높이는 방법 및 이 생체이용율이 높아진 파라세타몰을 함유한 제제 | |
| CN108503651B (zh) | 一种用于治疗脑卒中的螺环化合物 | |
| KR20210046115A (ko) | 니아신 유도체 및 이를 함유하는 약학 조성물 | |
| JP4366533B2 (ja) | 睡眠障害の治療剤 | |
| ES2361847T3 (es) | Mejorador de la insuficiencia renal. | |
| JPH0426676A (ja) | 新規ジテルペンアルカロイド及びジテルペンアルカロイド類を有効成分とする心疾患治療薬 | |
| EP0474438A1 (en) | Method for preventing or treating cerebrovascular disease employing the ACE-inhibitor ceronapril | |
| JP2007137896A (ja) | イブプロフェン含有医薬製剤 | |
| JP2026509292A (ja) | 腫瘍学的併用療法及びその使用方法 | |
| JP2007077116A (ja) | 臓器線維化抑制剤 | |
| RU2025106855A (ru) | Применение боратных производных в лечении нейродегенеративных заболеваний |